泌尿外科

订阅

MedSci主页 / 所有栏目 / 泌尿外科

Int J Cancer：多梳家族蛋白EZH2和EED在晚期前列腺癌中能够直接调控雄激素受体

2019-01-20 AlexYang MedSci原创

前列腺多梳蛋白雄激素受体
关注

多梳家族蛋白是细胞增殖和分化、器官发育以及致命性疾病起始和恶化的重要表观调控因子，其中包括了癌症。多梳家族蛋白（包括zeste同源物增强子蛋白2（EZH2））表达的上调能够促进细胞增殖、迁移和入侵以及癌细胞的代谢，还包括了癌症干细胞的自我更新。最近，有研究人员报道了EZH2和胚胎外胚层发育（EED）与雄激素受体（AR）各自均具有直接的互作。在AR阳性前列腺癌中，EZH2和EED能够调控AR的表达水

多梳家族蛋白是细胞增殖和分化、器官发育以及致命性疾病起始和恶化的重要表观调控因子，其中包括了癌症。多梳家族蛋白（包括zeste同源物增强子蛋白2（EZH2））表达的上调能够促进细胞增殖、迁移和入侵以及癌细胞的代谢，还包括了癌症干细胞的自我更新。最近，有研究人员报道了EZH2和胚胎外胚层发育（EED）与雄激素受体（AR）各自均具有直接的互作。在AR阳性前列腺癌中，EZH2和EED能够调控AR的表达水平和AR下游靶标。更重要的是，研究人员阐释了在癌症中，以小分子抑制剂阿司咪唑来以EZH2为靶标能够显著的抑制EZH2和AR的表达以及肿瘤的大小。最后，研究人员指出，他们的结果整体上表明了药理学上以EZH2为靶标可能是未来治疗晚期前列腺癌非常有希望的策略。原始出处：Liu Q， Wang G， Li Q et al. Polycomb Group Proteins EZH2 and EED Directly Regulate Androgen Receptor in Advanced Prostate Cancer. Int J Cancer. 10 Jan 2019.本文系梅斯医学（MedSc

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1953510, encodeId=341b195351024, content=<a href='/topic/show?id=b3ec60803a2' target=_blank style='color:#2F92EE;'>#期前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60803, encryptionId=b3ec60803a2, topicName=期前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4723380, createdName=yangcx0915, createdTime=Thu Jun 06 20:21:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746913, encodeId=6d431e46913a9, content=<a href='/topic/show?id=5fefe188e3' target=_blank style='color:#2F92EE;'>#Ezh2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7188, encryptionId=5fefe188e3, topicName=Ezh2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2a935872940, createdName=fusion, createdTime=Tue Jul 02 09:21:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350547, encodeId=0bc7135054ea7, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98691, encryptionId=a7689869104, topicName=雄激素受体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Jan 22 02:21:00 CST 2019, time=2019-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412783, encodeId=72d61412e8317, content=<a href='/topic/show?id=86cf59813ad' target=_blank style='color:#2F92EE;'>#晚期前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59813, encryptionId=86cf59813ad, topicName=晚期前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=776d2903072, createdName=zhyy89, createdTime=Tue Jan 22 02:21:00 CST 2019, time=2019-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358706, encodeId=e545358e0666, content=不错的作品，为我们探讨研究提供了方针，必须给点个赞了！, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Sun Jan 20 11:35:06 CST 2019, time=2019-01-20, status=1, ipAttribution=)]
    2019-06-06 yangcx0915

    #期前列腺癌#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1953510, encodeId=341b195351024, content=<a href='/topic/show?id=b3ec60803a2' target=_blank style='color:#2F92EE;'>#期前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60803, encryptionId=b3ec60803a2, topicName=期前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4723380, createdName=yangcx0915, createdTime=Thu Jun 06 20:21:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746913, encodeId=6d431e46913a9, content=<a href='/topic/show?id=5fefe188e3' target=_blank style='color:#2F92EE;'>#Ezh2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7188, encryptionId=5fefe188e3, topicName=Ezh2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2a935872940, createdName=fusion, createdTime=Tue Jul 02 09:21:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350547, encodeId=0bc7135054ea7, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98691, encryptionId=a7689869104, topicName=雄激素受体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Jan 22 02:21:00 CST 2019, time=2019-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412783, encodeId=72d61412e8317, content=<a href='/topic/show?id=86cf59813ad' target=_blank style='color:#2F92EE;'>#晚期前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59813, encryptionId=86cf59813ad, topicName=晚期前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=776d2903072, createdName=zhyy89, createdTime=Tue Jan 22 02:21:00 CST 2019, time=2019-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358706, encodeId=e545358e0666, content=不错的作品，为我们探讨研究提供了方针，必须给点个赞了！, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Sun Jan 20 11:35:06 CST 2019, time=2019-01-20, status=1, ipAttribution=)]
    2019-07-02 fusion

    #Ezh2#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1953510, encodeId=341b195351024, content=<a href='/topic/show?id=b3ec60803a2' target=_blank style='color:#2F92EE;'>#期前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60803, encryptionId=b3ec60803a2, topicName=期前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4723380, createdName=yangcx0915, createdTime=Thu Jun 06 20:21:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746913, encodeId=6d431e46913a9, content=<a href='/topic/show?id=5fefe188e3' target=_blank style='color:#2F92EE;'>#Ezh2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7188, encryptionId=5fefe188e3, topicName=Ezh2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2a935872940, createdName=fusion, createdTime=Tue Jul 02 09:21:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350547, encodeId=0bc7135054ea7, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98691, encryptionId=a7689869104, topicName=雄激素受体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Jan 22 02:21:00 CST 2019, time=2019-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412783, encodeId=72d61412e8317, content=<a href='/topic/show?id=86cf59813ad' target=_blank style='color:#2F92EE;'>#晚期前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59813, encryptionId=86cf59813ad, topicName=晚期前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=776d2903072, createdName=zhyy89, createdTime=Tue Jan 22 02:21:00 CST 2019, time=2019-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358706, encodeId=e545358e0666, content=不错的作品，为我们探讨研究提供了方针，必须给点个赞了！, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Sun Jan 20 11:35:06 CST 2019, time=2019-01-20, status=1, ipAttribution=)]
    2019-01-22 zhaojie88

    #雄激素受体#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1953510, encodeId=341b195351024, content=<a href='/topic/show?id=b3ec60803a2' target=_blank style='color:#2F92EE;'>#期前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60803, encryptionId=b3ec60803a2, topicName=期前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4723380, createdName=yangcx0915, createdTime=Thu Jun 06 20:21:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746913, encodeId=6d431e46913a9, content=<a href='/topic/show?id=5fefe188e3' target=_blank style='color:#2F92EE;'>#Ezh2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7188, encryptionId=5fefe188e3, topicName=Ezh2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2a935872940, createdName=fusion, createdTime=Tue Jul 02 09:21:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350547, encodeId=0bc7135054ea7, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98691, encryptionId=a7689869104, topicName=雄激素受体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Jan 22 02:21:00 CST 2019, time=2019-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412783, encodeId=72d61412e8317, content=<a href='/topic/show?id=86cf59813ad' target=_blank style='color:#2F92EE;'>#晚期前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59813, encryptionId=86cf59813ad, topicName=晚期前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=776d2903072, createdName=zhyy89, createdTime=Tue Jan 22 02:21:00 CST 2019, time=2019-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358706, encodeId=e545358e0666, content=不错的作品，为我们探讨研究提供了方针，必须给点个赞了！, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Sun Jan 20 11:35:06 CST 2019, time=2019-01-20, status=1, ipAttribution=)]
    2019-01-22 zhyy89

    #晚期前列腺癌#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1953510, encodeId=341b195351024, content=<a href='/topic/show?id=b3ec60803a2' target=_blank style='color:#2F92EE;'>#期前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60803, encryptionId=b3ec60803a2, topicName=期前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4723380, createdName=yangcx0915, createdTime=Thu Jun 06 20:21:00 CST 2019, time=2019-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746913, encodeId=6d431e46913a9, content=<a href='/topic/show?id=5fefe188e3' target=_blank style='color:#2F92EE;'>#Ezh2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7188, encryptionId=5fefe188e3, topicName=Ezh2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2a935872940, createdName=fusion, createdTime=Tue Jul 02 09:21:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350547, encodeId=0bc7135054ea7, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98691, encryptionId=a7689869104, topicName=雄激素受体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Jan 22 02:21:00 CST 2019, time=2019-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412783, encodeId=72d61412e8317, content=<a href='/topic/show?id=86cf59813ad' target=_blank style='color:#2F92EE;'>#晚期前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59813, encryptionId=86cf59813ad, topicName=晚期前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=776d2903072, createdName=zhyy89, createdTime=Tue Jan 22 02:21:00 CST 2019, time=2019-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=358706, encodeId=e545358e0666, content=不错的作品，为我们探讨研究提供了方针，必须给点个赞了！, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Sun Jan 20 11:35:06 CST 2019, time=2019-01-20, status=1, ipAttribution=)]
    2019-01-20 ylzr123

    不错的作品，为我们探讨研究提供了方针，必须给点个赞了！

    0

相关资讯

Urology：核磁共振成像确定的前列腺特异性抗原密度能够显著的改善前列腺癌活检的风险预测

最近，有研究人员评估了核磁共振成像（MRI）确定的前列腺癌特异性抗原（PSA）密度的预测价值和MRI对临床显著性前列腺癌（PCa）检测的解释能力情况。研究人员回顾性的分析了2014年9月和2016年12月之间研究人员所在单位的相关数据，这些数据是关于那些在活检之间接受前列腺MRI的男性患者数据，排除了那些积极监控的患者（n=372）。研究人员利用MRI确定的PSA密度、单独PSA和前列腺癌预防试验

Appl Immunohistochem Mol Morphol：免疫组化技术在前列腺病灶活检应用中的评估

免疫组化（IHC）在前列腺病灶评估中的使用还没有常规化，且其价值还没有评估。最近，有研究人员提取了2011年到2017年的病理组织切片报告，并对其进行了回顾和分析。研究共包括了4477个活检样本。这些样本通过病理严重程度分类（染色百分比），群体包括1184名良性案例（42%）；168个前列腺上皮内瘤案例（68%）；323个疑似案例（93%）；一级癌症（WHO1）：900 (78%)； 二级癌症(W

你知道自己的前列腺健康指数吗？

前列腺癌（PCa）是男性第二大常见恶性肿瘤，也是导致死亡的第五大癌症。 基于前列腺特异性抗原（PSA）检测的前列腺癌筛查可以帮助早期发现肿瘤，但越来越多的研究证明，尽管PSA具有较好的组织特异性，但其肿瘤特异性较差，会引起过度诊断和过度治疗。

CLIN CHEM：前列腺癌风险相关的单核苷酸多态性影响前列腺特异性抗原糖基化及其功能

前期，遗传相关研究报道染色体19q13.3的单核苷酸多态性（SNPs）与前列腺癌（PCa）风险相关。最近，据报道，编码前列腺特异性抗原（PSA）的激肽释放酶相关肽酶3（KLK3）基因的外显子3中的rs61752561SNP（Asp84Asn取代）与PCa风险密切相关（P = 2.3×10 -8）。然而，有关rs61752561 SNP对PCa风险的生物学贡献尚未阐明。

盘点：前列腺癌盘点

前列腺是男性生殖器附属腺中最大的实质性器官。由前列腺组织和肌组织构成。前列腺癌是指发生在前列腺的上皮性恶性肿瘤。2004年WHO《泌尿系统及男性生殖器官肿瘤病理学和遗传学》中前列腺癌病理类型上包括腺癌（腺泡腺癌）、导管腺癌、尿路上皮癌、鳞状细胞癌、腺鳞癌。其中前列腺腺癌占95%以上，因此，通常我们所说的前列腺癌就是指前列腺腺癌。梅斯医学小编整理了近期前列腺癌的研究进展，与大家一起分享学习！【1

Sci Rep：一个前列腺来源的共生表皮葡萄球菌菌株能够预防和减轻UPEC感染诱导的慢性前列腺炎

慢性前列腺炎/慢性盆腔疼痛综合症（CP/CPPS）是一种常见的综合症，并且治疗方法有限且发病原因未知。之前，有研究人员确定了疾病起始中病理感染的一个潜在角色。即从CP/CPPS患者中分离的尿路致病性大肠杆菌菌株CP1的尿道内感染能够诱导小鼠前列腺炎和触觉异常性疼痛。研究人员同样阐释了一个从健康个体分离的前列腺特异性表皮葡萄球菌NPI（非疼痛诱导）在小鼠模型中能够减少疼痛和炎症。最近，有研究人员关注